Flecainide acetate is under clinical development by InCarda Therapeutics and currently in Phase III for Atrial Fibrillation. According to GlobalData, Phase III drugs for Atrial Fibrillation have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Flecainide acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Flecainide acetate overview

Flecainide acetate (Inrhythm) is under development for the treatment of paroxysmal atrial fibrillation (PAF) and paroxysmal supraventricular tachycardia (PSVT). It is administered as an oral inhalational formulation (solution) using a nebulizer. The drug candidate acts by targeting sodium channel protein type 5 subunit alpha.

InCarda Therapeutics overview

InCarda Therapeutics (InCarda) is a biopharmaceutical company that concentrates on the development of transformative therapies for cardiovascular conditions through the inhalation route. The company’s lead product candidate includes InRhythm, an inhaled antiarrhythmic for acute treatment of paroxysmal atrial fibrillation. InRhythm is designed to improve the pharmacokinetic profile of the drug to enhance efficacy and improve the safety profile. InCarda also develops therapies for acute myocardial infarction, paroxysmal supraventricular tachycardia. The company has presence in the US and Australia. InCarda is headquartered in Newark, California, the US.

For a complete picture of Flecainide acetate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.